

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Chen et al.

Serial No.:

10/046,681

Group Art Unit No.:

1614

Filed:

January 10, 2002

Examiner: Richard L. Raymond

For:

SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE

Docket No.:

A-733A

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Under the guidelines of 37 C.F.R. 1.97, applicants submit a copy of each of the references listed on the attached supplemental PTO-1449 (Modified) form for consideration by the Examiner.

Applicant, by the undersigned attorney/agent, certifies that no information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned, after making reasonable inquiry, was known to any individual designated in § 1.56(c) more than three months pursuant to 37 C.F.R. 1.97(e)(1) prior to the filing of this statement.

Applicant(s) request(s) consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc. An original and one copy of this paper are enclosed.

Respectfully submitted,

Joseph W. Bulock

Attorney/Agent for Applicant(s)

Registration No.: 37,103 Phone: (805) 447-7966

Date: May 6, 2005

EXPRESS MAIL CERTIFICATE

EL732819232US

Date of Deposit:

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Sherry St. Andrew

Please send all future correspondence to:

U.S. Patent Operations/JWB
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

Modified Form PTO-1449

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

Atty. Docket No. Serial No.

A-733A 10/046.681

Applicant

Chen et al.

Filing Date

January 10, 2002 Group 1614

U.S. PATENT DOCUMENTS DOCUMENT NUMBER CLASS SUB-**FILING DATE IF** CLASS APPROPRIATE INITIALS TE TRATE 21 Oct 2003 Beight et al. 6,635,657 B1 **A7** 6,605,626 B2 12 Aug 2003 Beight et al. 9 July 2002 Beight et al. **A8** 6,417,200 B1 Beight et al. **A9** 6,372,759 B1 16 Apr 2002 6 Nov 2001 Beight et al. A10 6,313,122 B1 6 Nov 2001 Beight et al. A11 6,313,151 B1 26 Aug 2003 Beight et al. 6,610,704 B1 A12 A13 2003/0069250 A1 10 Apr 2003 Zhu et al. Ernst et al. 2004/0254185 A1 16 Dec 2004 A14 A15 6,051,713 18 Apr 2000 Teng et al. Satzinger et al. 28 Mar 1989 A16 4,816,485 15 Aug 1989 Satzinger et al. A17 4,857,662 5 Dec 2000 Arita et al. A18 6,156,766 23 Mar 1982 Parg et al. A19 4,321,371 2004/0102441 A1 A20 27 May 2004 Krueger et al. 24 Sep 1996 Ashton et al. A21 5,559,135 15 July 2003 Weichert et al. A22 6,593,352 B2 9 Dec 2003 Song et al. A23 6,660,755 B2 Ohuchida et al. 10 Sep 2002 6,448,290 B1 A24 A25 3,822,277 2 July 1974 Claude Dufour 23 Jun 1998 Gaeta et al. A26 5,770,613 5,571,912 5 Nov 1996 Grozinger et al. A27 **Gunther Schmidt** 15 Oct 1968 A28 3,406,168 A29 6,008,234 28 Dec 1999 Kochanny et al. Momose et al. 2004/0063775 A1 1 Apr 2004 A30

EXAMINER:	Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet	2	Of	2

						_		Sheet 2	2 Of	2
Modified For	m PTO-14	49		Atty. Docke			Serial	No.		
LIST OF REFERENCES CITED BY APPLICANT			Applicant	A-733A			10/046.6			
	•	FLEKENCES CITED BY	APPLICANT	уфричан	Chen et al.					
QIP !	(Use several sheets if necessary)			Filing Date			Group			
(Use several silects if flecessary)				January 10, 20	02	1614				
MAY 0 6		4_0	U.S. PATEN	T DOCUM	ENTS					
EXAMINER'S POITIALS TRAI	18	DOCUMENT NUMBER	DATE		NAME	CLAS	SS	SUB- CLASS	FILING APPRO	
GTRA	A31	2003/0195192 A1	16 Oct 2003		laviv et al.					
	A32	2003/0195195 A1	16 Oct 2003	Haviv et al.						
	A33	2005/0032816 A1	10 Feb 2005	Ernst et al.						
	A34	6,794,397 B2	21 Sep 2004	Cai et al.						
	A35	2005/0054654 A1	10 Mar 2005	Huth et al.						
	A36	6,271,237 B1	7 Aug 2001	Gale	mmo, Jr. et al.				<u></u>	
			FOREIGN PAT	ENT DOCU	MENTS					
EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE		COUNTRY	CL	ASS	SUB- CLASS	TRANSI YES	LATION NO
	B27	WO 03/068235 A1	21 Aug 2003		PCT					
	B28	WO 03/068232 A1	21 Aug 2003		PCT					
	B29	EP 0 429 987 A2	5 Jun 1991	Europe						
	B30	EP 0 393 529 B1	30 Jun 1993	Europe						
	B31	EP 0 410 148 A1	30 Jan 1991	Europe						
10	B32	EP 0 393 529 A1	24 Oct 1990		Europe					
EXAMINER'S INITIALS	C	THER DOCUMENTS	(Including Pub	olisher, Au	ithor, Title, Date	e, Perti	nent	Pages	, Etc.)	
	C9	Proudfoot et al., "Novel	Non-nucleoside Ir	hibitors or I	HIV-1 Reverse Tra	nscripta	se. 3.	Dipyrido	[2,3-b:	2',3'-

e]diazepinones", J. Med. Chem., 38:1406-1410 (1995). Smrckova-Voltrova et al., "Structure and Properties of Quaternized 2- and 4-aminonicotinamides", Collect. C10 Czech. Chem. Commun., 50:1009-1015 (1995). Samvelyan et al., "Discussion of Some New Amino Acid Derivatives of Nicotinic Acid and Their C11 Antisoporific Properties", Farmakologiia I Toksikologiia, 49(3):35-37 (1986). Hargrave et al., "Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 1. Tricyclic C12 Pyridobenzo- and Dipyridodiazepinones", J. Med. Chem., 34:2231-2241 (1991). Adams et al., "Discovery and Development of a Non-nucleoside Reverse Transcriptase Inhibitor", Royal C13 Society of Chemistry, Recent Advances in the Chemistry of Anti-infective Agents, 19:282-296 (1993).

,	
EXAMINER:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPE	P 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next

communication to applicant.